07:18 AM EDT, 09/18/2025 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Thursday it has expanded its FLAMINGO-01 clinical trial to Ireland.

The company said FLAMINGO-01 is a phase 3 clinical trial designed to evaluate the safety and efficacy of GLSI-100, a drug candidate intended to prevent breast cancer recurrences.

The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks, with plans to open up to 150 sites globally.

Greenwich LifeSciences ( GLSI ) said it is collaborating with Janice Walshe, who will be serving as the national principal investigator in Ireland for FLAMINGO-01.

The company also said its application to European regulators has been formally approved, adding Ireland as an approved country in addition to Spain, France, Germany, Italy, Poland, Romania, and the US.

Greenwich LifeSciences ( GLSI ) shares were up over 2% in recent premarket activity Thursday.

Price: 11.40, Change: +0.25, Percent Change: +2.24